Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...
Barchart on MSN2d
Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?
Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...
The Pharma Letter5d
Amgen and Kyowa Kirin announce rocatinlimab Phase III success
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
The Pharma Letter6d
The week in pharma: action, reaction and insight – week to March 7
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...
PipelineReview.com6d
Amgen and Kyowa Kirin provide top-line results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
About the ROCKET Phase 3 Program ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in ...